Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zai Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zai Lab's regulatory disclosures and financial reporting.
Zai Lab Ltd Chairperson and CEO exercised stock options and reported related ADS transactions. On March 10, 2026, the reporting person exercised options to acquire 261,092 American Depositary Shares (ADSs) at $1.74 per ADS and received an additional 2,655 ADSs upon vesting of restricted share units (RSUs). To cover taxes on RSU vesting, 116,936 ADSs were automatically sold at $19.41 per ADS. On March 11, 2026, 1,067 ADSs were sold at $19.084 per ADS under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, the reporting person directly held 1,109,905 ADSs, with 461,092 stock options and 7,965 RSUs remaining outstanding. Each ADS represents ten Ordinary Shares of Zai Lab.
ZLAB reported a Form 144 notice evidencing proposed sales of American Depositary Shares by Ying Du. The filing lists four dispositions of 50,000 ADS each on 03/04/2026, 03/05/2026, 03/06/2026 and 03/09/2026, with reported gross proceeds shown per trade.
Zai Lab Ltd chairperson and CEO Du Ying reported option exercises and share sales under a pre-arranged trading plan. On March 6 and March 9, 2026, Du Ying exercised stock options for a total of 100,000 American Depositary Shares at an exercise price of $1.74 per ADS and then sold 100,000 ADS in open-market transactions at weighted average prices of $19.4187 and $19.0293 per ADS. Following these transactions, Du Ying directly holds 964,161 ADS. The filing notes that each ADS represents ten ordinary shares and that all trades were executed pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the sales were pre-scheduled rather than opportunistic.
ZLAB filed a Form 144 notice relating to sales of American Depositary Shares. The filing lists an intended sale of 50,000 ADS on 03/09/2026 through Fidelity Brokerage Services LLC and records executed sales by Ying Du of 50,000 ADS on 03/04/2026, 50,000 ADS on 03/05/2026, and 50,000 ADS on 03/06/2026 with reported dollar amounts of $958,155.00, $961,055.00, and $959,000.00 respectively.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an open-market sale of 15,569 American Depositary Shares at $19.06 per ADS on March 5, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.
Following this transaction, he holds 3,517 ADS directly. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are described as fully fungible.
Zai Lab Ltd chairperson and CEO Du Ying reported exercising stock options and selling shares in early March 2026. On March 4–5, 2026, Du Ying exercised options for a total of 100,000 American Depositary Shares (ADS), described as derivative exercises or conversions at $1.74 per ADS.
Over the same two days, Du Ying sold 100,000 ADS in open-market transactions at weighted average prices of $18.7769, $19.3176, and $19.2211 per ADS. After these trades, Du Ying directly owned 964,161 ADS. Each ADS represents ten ordinary shares, and all trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
ZLAB reported proposed and recent insider sales of American Depositary Shares: a proposed sale of 50,000 ADS dated 03/06/2026 and two reported sales of 50,000 ADS each on 03/04/2026 and 03/05/2026 by Ying Du. The proposed sale is listed as an issuer option exercise with cash consideration and references an option granted on 08/25/2016.
Zai Lab Ltd officer Rafael Amado reported an open‑market sale of 10,000 American Depositary Shares (ADS) on 2026-03-03 at a price of $17.38 per ADS. After this transaction, he directly held 42,391 ADS.
Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The sale was effected under a Rule 10b5‑1 trading plan adopted by the reporting person on November 15, 2025.
ZLAB filed a Form 144 reporting a proposed sale of 15,569 American Depositary Shares. The filing lists recent compensation-related restricted stock vesting of 4,238, 2,608, and 8,723 ADS on 04/01/2025, 04/03/2025, and 06/25/2025 respectively. The excerpt shows a prior sale by Frazor T. Edmondson of 8,651 ADS on 12/16/2025 for 148,278.14.